-
SQNM Likely To Develop High Margin Diagnostic Products
Wednesday, March 17, 2010 - 2:48pm | 81Analysts at Cantor Fitzgerald maintain their "buy" rating on Sequenom (NASDAQ: SQNM). The target price for SQNM has been reduced from $16 to $13. According to Cantor Fitzgerald, the target has been lowered to reflect anticipated dilution and settlement of a class action suit. Cantor Fitzgerald...
-
Tuesday March 16th ETF Movers: GDX, FBT
Tuesday, March 16, 2010 - 5:01pm | 311In midday trading Tuesday, the Gold Miners ETF (GDX) is outperforming other ETFs, up about 2.6% on the day. Components of that ETF showing particular strength include shares of Nevsun Resources (NSU), up about 5.4% and shares of Lihir Gold (LIHR), up about 4.6% on the day. And underperforming other...
-
Setback for MannKind - Analyst Blog
Tuesday, March 16, 2010 - 2:17pm | 345MannKind Corp. (MNKD) suffered a major setback with respect to its lead product, Afrezza, inhaled insulin for treating type I and type II diabetes. The company received a complete response letter (CRL) from the US Food & Drug Administration (FDA) recently. The FDA has asked MannKind for...
-
Data On SQNM’s T-21 Diagnostic Test To Act As A Catalyst
Tuesday, March 16, 2010 - 1:40pm | 125Analysts at Auriga reiterate their "hold" rating on Sequenom (NASDAQ: SQNM). The target price for SQNM is set to $4. According to Auriga, Sequenom has reported its Q4 revenues ahead of the estimates, driven by impressive Mass-array sales. However, SQNM’s EPS fell short of the expectations due to...
-
Sequenom Inc. (SQNM) May Now Move Into Bearish Mode Below $6.02
Tuesday, March 16, 2010 - 12:02pm | 105Sequenom Inc. (NASDAQ: SQNM) dropped 21% to $6.10 in first half of the session of Tuesday. The biotechnology company Sequenom Inc. (SQNM) posted a Q4 loss excluding some items of 30 cents a share, which were much wider than the average analysts’ estimates. Sequenom Inc. (SQNM) slipped below its 20...
-
A Peek Into Today’s Analysts Ratings (CVH, ONXX, PRXL, SBUX, WU, WYN, PSYS, UAM, VRUS)
Tuesday, March 16, 2010 - 10:43am | 360Some of today’s upgrades, downgrades and initiations are: Upgrades Goldman upgraded Coventry Health (NYSE: CVH) from “sell” to “neutral.” The upgrade in the rating is based on valuation, according to Goldman. CVH’s shares lost 1.25% in after hours trading. Analysts at Goldman upgraded Onyx...
-
Sequenom (SQNM) Shares Plummet 20%
Tuesday, March 16, 2010 - 9:55am | 98Shares of Sequenom, Inc. (Nasdaq: SQNM) were down 20% shortly after the market opened. The falling stock price started during Monday's after hours trading, when Sequenom released a disappointing earnings report. Sequenom reported late Monday a larger than expected 4th quarter loss of $18.4 million...
-
Leerink Swann Rates Medivation (MDVN) Market Perform
Tuesday, March 16, 2010 - 8:50am | 178Leerink Swann analysts Howard Liang and Jonathan Eckard rated shares of Medivation, Inc. (Nasdaq: MDVN) a Market Perform with a valuation of $14. The analysts said that the negative readout for the Phase III CONNECTION trial for Dimebon, without any efficacy signal, leads them to believe that...
-
Benzinga’s Top Pre-Market Losers (BSX, SQNM, UWBK, PSEC)
Tuesday, March 16, 2010 - 8:23am | 271Boston Scientific Corporation (NYSE: BSX) decreased 0.15% to $6.79 in the pre-market session. Boston Scientific announced yesterday that it has received Australian Therapeutic Goods Administration approval for its PROMUS Element and TAXUS Element Stent Systems, the Company's drug eluting stent (DES...
-
Sequenom Sinking In The After Hours (SQNM)
Monday, March 15, 2010 - 5:28pm | 120Sequenom (NASDAQ: SQNM) reported their quarterly earnings after the opening bell today. The company recorded a net loss of $18.4 million or $0.30 per share for the fourth quarter, compared to a loss of $15.4 million or $0.25 per share in last year's corresponding quarter. Consensus analysts'...
-
Bayer Downgraded to Underperform - Analyst Blog
Monday, March 15, 2010 - 11:15am | 387We have recently downgraded our recommendation on Bayer (BAYRY) to Underperform from Neutral. During the fourth quarter of 2009, the company’s core earnings per share came in at €0.90 surpassing €0.71 reported in the year-ago period. Bayer has been shifting its focus towards its HealthCare...
-
Jim Cramer's Lightning Round OT Comments (SNV, MDVN, RF, FHN, HBAN, BBT)
Friday, March 12, 2010 - 8:40pm | 331CNBC Mad Money's Jim Cramer said in the segment of his show called Lightning Round OT that Synovus Financial Corp. (NYSE: SNV) could be a home run. Cramer visited a presentation about this company at Citigroup (NYSE: C), and he likes what he heard there. Synovus (SNV) has to do some refinancing,...
-
Merck To Continue Its M&A Spree (MRK, MIL)
Friday, March 12, 2010 - 7:04pm | 141Merck (NYSE: MRK) is planning to continue its M&A activities following the conclusion of its $6 billion Millipore (NYSE: MIL) deal. Merck’s (MRK) chief executive officer Karl-Ludwig said, "We have indeed a few ideas. Acquisitions are a part of our strategy." Merck’s focus is to diversify its...
-
Benzinga’s Top Pre-Market Gainers (YONG, RFMD, KIRK, CAGC, EXEL)
Friday, March 12, 2010 - 9:28am | 279Yongye International, Inc. (NASDAQ: YONG) increased 5.49% to $9.03 in the pre-market session. Yongye International announced today that its operating entity in China, Yongye Nongfeng Biotechnology, signed a preliminary agreement with a local supplier of humic acid to purchase an undeveloped lignite...
-
These Biotech ETFs Gain Access To A Broader Array Of Biotech Companies
Wednesday, March 10, 2010 - 4:46pm | 169“Last week a number of biotech players, including Millipore (MIL), OSI Pharmaceuticals (OSIP), Intermune (ITMN) and Sequenom (SQNM) turned in double-digit gains in the volatile health care subsector. On the other side, health care stocks do fall, leaving investors with a bitter taste. For example,...